Response rate or time to progression as predictors of survival in trials of metastatic colorectal cancer or non-small-cell lung cancer: a meta-analysis.
暂无分享,去创建一个
N. Freemantle | S. Hill | R. Ward | K. Johnson | C. Ringland | B. Stokes | D. M. Anthony | A. Irs | Danielle M Anthony
[1] A. Miller,et al. Reporting results of cancer treatment , 1981, Cancer.
[2] Douglas G. Altman,et al. Practical statistics for medical research , 1990 .
[3] R. J. Hayes,et al. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. , 1995, JAMA.
[4] M. van Glabbeke,et al. New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.
[5] Geert Molenberghs,et al. Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis , 2000, The Lancet.
[6] Harold I Feldman,et al. Individual patient‐ versus group‐level data meta‐regressions for the investigation of treatment effect modifiers: ecological bias rears its ugly head , 2002, Statistics in medicine.
[7] R. Temple. Policy developments in regulatory approval , 2002, Statistics in medicine.
[8] T. Hickish,et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. , 2004, The New England journal of medicine.
[9] Stephanie Green,et al. Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria , 1992, Investigational New Drugs.
[10] Daniel J Sargent,et al. Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] Michael Hughes. The Evaluation of Surrogate Endpoints in Practice: Experience in HIV , 2005 .
[12] Thomas R Fleming. Objective response rate as a surrogate end point: a commentary. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] M. Ahn,et al. Comparison of RECIST and WHO response criteria in metastatic colorectal carcinoma , 2005 .
[14] M. Sormani,et al. Objective response to chemotherapy as a potential surrogate end point of survival in metastatic breast cancer patients. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] M. Buyse,et al. Surrogate threshold effect: an alternative measure for meta-analytic surrogate endpoint validation. , 2006, Pharmaceutical statistics.
[16] Geert Molenberghs,et al. Evaluation of Surrogate Endpoints , 2006, Handbook of Statistical Methods for Randomized Controlled Trials.
[17] Marc Buyse,et al. Surrogate threshold effect: an alternative measure for meta‐analytic surrogate endpoint validation , 2006, Pharmaceutical statistics.